Hansoh Pharmaceutical (03692.HK): Inebilizumab Injection (Xinyue®) New Indication for IgG4-Related Disease Granted Priority Review by NMPA

HONG KONG, Feb. 8, 2025 (APP - Smart Finance) -- Hansoh Pharma (03692) announced on February 8, 2025, based on Xinyue^®(The positive results of the global pivotal Phase III trial MITIGATE for Inebilizumab Injection, which is used for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD), have led to the new indication being granted priority review and approval by the National Medical Products Administration (NMPA).)

Inebilizumab is a CD19 B-cell depleting antibody.